Chiesi TOTAL care

Physician Prescription/Order & Statement of Medical Necessity

Ferriprox TWICE-A-DAY deferiprone 1000 mg tablets

Ferriprox deferiprone
1000 mg tablets
500 mg tablets
Oral solution 100 mg/mL

Please fax completed form to Chiesi Total Care℠ staff at 1-866-565-7794.

PATIENT INFORMATION

Patient Name (Last, First) _____

Social Security # _____- _____- _____ Sex: ☐ Male ☐ Female Date of Birth _____ (mm/dd/yyyy)

Address _____ City _____ State_____ Zip_____

Primary Phone (Required) _____ Cell Phone _____ Language: ☐ English ☐ Other _____

Please attach copies of patient insurance and prescription cards – front and back.

MEDICAL INFORMATION

Diagnosis: ☐ Transfusional Iron Overload E83.111

Due to: ☐ Beta Thalassemia D56.1 ☐ Other Thalassemias D56.8 ☐ Other Anemias _____
☐ Sickle Cell Disease D57.1 ☐ Other Sickle Cell Disease D57.8 ☐ Other_____

Height_____ inches or _____cm Weight _____ lb or _____ kg Allergies: ☐ None or Specify_____

Lab test	Results	Date (mm/dd/yyyy)
Most recent serum ferritin level (acceptable level <500 ng/mL)		

If available please provide the following	Results	Date (mm/dd/yyyy)
Most recent liver iron concentration value (acceptable level <3,000 μg/g dry weight)		
Most recent cardiac MRI T2* value (acceptable level >20 ms)		

Prior Chelation Therapy _____ **Current Chelation Therapy** _____

Transfusion History

Approximate number of blood units/month	
Approximate interval between transfusions (weeks)	

FERRIPROX® (DEFERIPRONE) PRESCRIPTION/ORDER

TWICE-A-DAY FORMULATION

☐ **Ferriprox (deferiprone) Twice-A-Day tablets 1000 mg†**
Sig: Take _____tablets po BID

THREE-TIMES-A-DAY FORMULATION†

☐ Ferriprox (deferiprone) oral solution 100 mg/mL
Sig: Take _____mL po TID or see Rx attached

† 500 mg and 1000 mg Three-Times-A-Day tablets are still available. Talk to your pharmacist for more information.

(Standard dose is 75-99 mg/kg/day divided into 2 doses/day for Twice-A-Day tablets or 3 doses/day for oral solution.) **Dispense 30-day supply.**
Number of Refills _____

PHYSICIAN/OFFICE INFORMATION

Prescriber's Name (print) _____ Office Phone _____

Practice/Group Name _____ Office Fax _____

Address _____ Suite_____ License # _____

City_____ State_____ Zip_____

Office Contact Person _____ NPI #_____

By signing below, I certify that I am part of the Chiesi Total Care Program, that the therapy described above is medically necessary, and that the information provided is accurate to the best of my knowledge. I also attest that I have obtained the patient's authorization to release the above information and such other personal information as may be necessary to the Chiesi Total Care Program and/or their agents. If the patient is 18 years old or younger, I attest that I have obtained permission from the patient's legal guardian.

Prescriber's Signature _____ _____ Date _____
Substitution Permitted Dispense as Written

Ferriprox Twice-A-Day is available as 1000 mg BID tablets.
Ferriprox is available as 1000 mg and 500 mg (immediate release) Three-Times-A-Day tablets and as 100 mg/mL oral solution.
Please call 1-866-758-7071 if you have questions regarding this form, or contact Chiesi Total Care.
Please see Important Safety Information, including boxed WARNING, on the back.
Chiesi Total Care Program offered through EVERSANA Life Science Services Specialty Pharmacy.

Indication

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload due to:

- thalassemia syndromes
- sickle cell disease or other anemias

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age; Ferriprox Oral Solution is indicated in patients ≥3 years of age.

Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Important Safety Information

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

- **Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.**
- **Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.**
- **Interrupt Ferriprox if infection develops and monitor the ANC more frequently.**
- **Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.**

Ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations.

In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with Ferriprox developed increased ALT values. Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. In pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with Ferriprox developed increased ALT values. Monitor serum ALT values monthly during therapy with Ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels. Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc, and supplement in the event of a deficiency.

Ferriprox can cause fetal harm. Advise females of reproductive potential to use an effective method of contraception during treatment with Ferriprox and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Ferriprox and for at least three months after the last dose. Advise females not to breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Avoid co-administration of Ferriprox with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of Ferriprox and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

The most common adverse reactions in patients with thalassemia (incidence ≥6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. The most common adverse reactions in patients with sickle cell disease or other anemias (incidence ≥6%) are pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, ALT increased, AST increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea.

Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.

Advise patients to avoid alcohol while taking Ferriprox tablets (twice-a-day). Consumption of alcohol while taking Ferriprox tablets (twice-a-day) may result in more rapid release of deferiprone.

Please see full Prescribing Information, including boxed WARNING and Medication Guide.

Chiesi Total Care Program offered through EVERSANA Life Science Services Specialty Pharmacy.

For more information, visit ferriprox.com.

PP-F-0131 V3.0 2021

Ferriprox® TWICE-A-DAY
deferiprone
1000 mg tablets

Ferriprox®
deferiprone
1000 mg tablets
500 mg tablets
Oral solution 100 mg/mL